TSG-6 has been considered as a therapeutic target in many inflammation-related diseases, including atherosclerosis (50), osteoarthritis (51), acute myocardial infarction (52), subarachnoid hemorrhage-induced early brain injury (53), inflammatory lung injury (54), and alcoholic hepatitis (55). This evidence concerns the gene TNFAIP6 and alcoholic hepatitis.